Satsuma Pharmaceuticals Inc (STSA) is trading 13% higher at $7.84 today. Shares of the stock are quickly outperforming other names in the space on what is turning out to be a slightly melancholic day for the Health Care sector.
- The drug STS101 demonstrated a favorable safety and tolerability profile in a clinical trial.
- Over 8,000 migraine attacks were treated with the drug.
Satsuma Pharmaceuticals Inc has been trading between a 52-week high of $7 and a 52-week low of $2.51. The stock has a market cap of $248 Million.
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product candidate for the acute treatment of migraine. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. DHE products have long been recommended as a first-line therapeutic option for the acute treatment of migraine and have significant advantages over other therapeutics for many patients.